Guideline to Implement livelihood allowance for Cancer, Kidney & paralyzed patients from spinal injuries
Guideline to Implement livelihood allowance for Cancer, Kidney & paralyzed patients from spinal injuries
The government has decided to provide Rs 5,000 as a monthly social welfare allowance to those people suffering from grave kinds of diseases.
OpenWHO is WHO’s new, interactive, web-based platform that offers online courses to people preparing to work in epidemics, pandemics and health emergencies or already doing so.The OpenWHO platform delivers WHO’s and partners’ expertise closer to where it is needed and provides information in user-friendly formats for frontline responders and decision-makers. The platform is managed by WHO’s Department for Infectious Hazards Management, in Geneva, Switzerland.
Users take part in a worldwide, social learning network that is based on interactive, online courses and materials covering a variety of subjects. OpenWHO also serves as a forum for the fast sharing of public health expertise and in-depth discussion and feedback on key issues.
Recent Public Health Jobs
[catlist id=112 numberposts=35]
Job vacancies (All Health related):
[catlist id=110 numberposts=35]
Consultancy :
[catlist id=47 numberposts=15]
Opportunities:
[catlist id=26 numberposts=20]
Recent Fellowships & Scholarships
[catlist id=115 numberposts=15]
Conferences :
[catlist id=28 numberposts=25]
Public Health :
[catlist id=25 numberposts=25]
Important Notices:
[catlist id=111 numberposts=15]
Public Health Important Days:
[catlist id=108 numberposts=15]
Public Health News:
[catlist id=139 numberposts=15]
National Plan Policies & Documents:
[catlist id=33 numberposts=15]
International Plan Policies & Documents:
[catlist id=124 numberposts=15]
EOI/RFP :
[catlist id=48 numberposts=15]
Public Health Education :
[catlist id=8 numberposts=25]
Tips & Techniques:
[catlist id=51 numberposts=25]
Public Health Presentations:
[catlist id=127 numberposts=25]
Delhi TB Summit: WHO South-East Asia countries commit to intensified efforts, concrete progress to End TB
Delhi TB Summit: WHO South-East Asia countries commit to intensified efforts, concrete progress to End TB
SEAR/PR/1683
New Delhi, 14 March 2018: Tracking progress to eliminate tuberculosis, Member countries of WHO South-East Asia Region today committed to further intensifying efforts to ensure rapid and concrete progress to End TB by 2030.
In a statement adopted at the Delhi End TB Summit here, member countries unanimously agreed to actualizing and intensifying essential actions agreed to in the Delhi Call to Action which was adopted in March last year to accelerate efforts to End TB in the Region, host to one fourth of the global population but a disproportionate 46% of the global TB burden.
Welcoming the statement, Dr Poonam Khetrapal Singh, Regional Director for WHO South-East Asia, said, “it gives shape to our momentum and aspirations, and does so by setting out a series of strategic priorities which include establishing strong leadership of TB programmes at the national level; increasing budgetary and human resource allocations to TB programmes from domestic and global sources; enabling each and every TB patient to access the best possible care available; and supplementing medical care for TB with social and financial protection.”
Reviewing efforts being made to end TB since the adoption of the Delhi Call for Action on 16 March 2017, Member countries noted that though efforts have been strengthened with increased attention, investments and initiatives; the stepped-up response was falling short of what was required to reach the critical thresholds for ending TB.
The Member countries of the Region stressed their firm intent to collectively reach out to 2 million missing TB cases and 150 000 multidrug-resistance cases by 2020 and implement a response that is demonstrably adequate for ending TB.
In the statement, the countries committed to multisectoral and empowered national initiatives, reporting to the highest levels of government, to lead the TB programme.
The Member countries committed to increasing budgetary and human resource allocations by governments as well as by their global, domestic and other partners so as to ensure that national TB plans are fully funded.
They also committed to universal access to comprehensive, integrated TB care and prevention services, to achieve universal health coverage as committed to in the Sustainable Development Goals, by enabling the best possible care to each and every person, including migrants, the aged and other high-risk populations, living with any form of TB including drug-resistant TB and TB-HIV co-infections.
To address the challenge of TB in a holistic manner, the Member countries agreed to supplement medical care for TB with social and financial protection in both high and lower incidence countries.
As member countries committed to ‘working together to end TB’, WHO reiterated that it stands with the Stop TB Partnership and all partners to make that vision a reality.
Hosted by the Ministry of Health and Family Welfare, Government of India, the World Health Organization and the Stop TB Partnership, the Delhi End TB Summit 2018 was inaugurated yesterday by the Prime Minister of India, Mr Narendra Modi.
The Stop TB Partnership’s Executive Director, Dr Lucica Ditiu, and the Global Fund’s Executive Director, Mr Peter Sands, are among the prominent health leaders attending the week-long meeting. The health ministers of a number of countries including Sri Lanka, Indonesia, Bangladesh, Nigeria, Mozambique, Zimbabwe, Kazakhstan and Peru are also participating.
The Summit sets the stage for the September 2018 United Nations High-Level Meeting on TB. For the first time TB will be discussed in the UN General Assembly at the Heads of State level. The UN high-level meeting is expected to endorse an ambitious set of goals to put the world on course to ending TB.
WHO MEDIA CENTRE
Egypt: first country in Eastern Mediterranean region to eliminate lymphatic filariasis
12 March 2018 | Cairo | Geneva – Egypt becomes the first country in the Eastern Mediterranean Region of the World Health Organization (WHO) and the latest in the world to eliminate lymphatic filariasis (LF) as a public health problem.
Egypt’s success comes after almost two decades of implementing sustained control and prevention measures (including mass treatment of populations) and surveillance in affected/at-risk localities.
Egypt’s struggle to overcome lymphatic filariasis (also known as elephantiasis) is perhaps one of the oldest in the history of public health, with field activities going back to the early 20th century. Its clinical manifestations are shown in pharaonic statues and works of art, and are described in early Arabic literature, although its causal agent, the parasite Wuchereria bancrofti, was first documented there in 1874.
The disease burden was fully appreciated in the 20th century through large-scale surveys, which revealed its endemicity in rural areas, especially in the eastern Nile Delta region, where clinical manifestations such as lymphoedema and hydrocele (swollen limbs and genitals) were commonly observed.
Lymphatic filariasis is caused by infection with parasitic worms living in the lymphatic system. The infection impairs the lymphatic system triggering abnormal enlargement of body parts, causing pain, severe disability and social stigma.
The larval stages of the parasite (microfilaria) circulate in the blood and are transmitted from person to person by mosquitoes.
Manifestation of the disease after infection takes time and can result in an altered lymphatic system, causing abnormal enlargement of body parts, and leading to severe disability and social stigmatization of those affected.
Almost 856 million people in 52 countries worldwide remain threatened by LF and require preventive treatment to stop its spread. Regular MDA reduces the density of microfilariae in the bloodstream and prevents the spread of parasites to mosquitoes.
MDA can interrupt the transmission cycle when conducted annually for 4–6 years with effective coverage of the total population at risk.
Salt fortified with DEC has also been used in a few settings to interrupt the transmission cycle.
Parasites that cause LF are transmitted by four main types of mosquitoes: Culex, Mansonia, Anopheles and Aedes.
READ MORE: WHO MEDIA CENTRE
[irp posts=”15896″ name=”Govt launching anti-filariasis campaign”]
[irp posts=”7928″ name=”Diseases Control Program in Nepal : Lymphatic Filariasis”]
PM Shri Narendra Modi inaugurates End-TB Summit in Vigyan Bhawan, New Delhi.
PM Shri Narendra Modi inaugurates End-TB Summit in Vigyan Bhawan, New Delhi.
The Delhi End TB Summit 2018 is starting today and inaugurated by the Prime Minister of India, Narendra Modi.
As part of the summit, health ministers and programme heads from WHO South-East Asia Region will review accelerated efforts being made by countries since the adoption of Delhi Call to Action. The Regional Director, Dr Poonam Khetrapal Singh, had announced ending TB as a flagship programme in the Region, at the Delhi Call to Action. Since then, countries in the Region have beefed up efforts to end TB. India, which had set a 2025 target, is matching it up with increased funding and efforts to proactively detect and treat patients. (WHO)
PM Shri Narendra Modi inaugurates End-TB Summit in Vigyan Bhawan, New Delhi
WHO issues new guidance on tobacco product regulation towards maximum protection of public health
WHO issues new guidance on tobacco product regulation towards maximum protection of public health
9 MARCH 2018 – CAPE TOWN: The World Health Organization (WHO) has launched new guidance on the role tobacco product regulation can play to reduce tobacco demand, save lives and raise revenues for health services to treat tobacco-related disease, in the context of comprehensive tobacco control.
A new guide, “Tobacco product regulation: Building laboratory testing capacity”, and a collection of country approaches to regulation of menthol, presented in the publication titled “Case studies for regulatory approaches to tobacco products – Menthol in tobacco products” have been launched at the 2018 World Conference on Tobacco or Health in Cape Town, South Africa.
Many countries have developed advanced policies to reduce the demand for tobacco, which kills over 7 million people annually, but governments can do much more to implement regulations to control tobacco use, especially by exploiting tobacco product regulation.
Dr Douglas Bettcher, WHO’s Director of the Department for the Prevention and Control of Noncommunicable diseases (NCDs), said “The WHO Framework Convention on Tobacco Control (WHO FCTC), a global treaty established under the auspices of the WHO to combat the tobacco epidemic, has played a critical role in tobacco control. The launch of these important publications will further aid the implementation of Articles 9 and 10 of the WHO FCTC, contributing to building tobacco product regulation capacity in WHO Member States”.
He further said “Tobacco product regulation is an under-utilized tool which has a critical role to play in reducing tobacco use. The tobacco industry has enjoyed years of little or no regulation, mainly due to the complexity of tobacco product regulation and lack of appropriate guidance in this area. These new tools provide a useful resource to countries to either introduce or improve existing tobacco product regulation provisions and end the tobacco industry ‘reign’.”
“Only a handful of countries currently regulate the contents, design features and emissions of tobacco products,” says Dr Bettcher. “This means that tobacco products are one of the few openly available consumer products that are virtually unregulated in terms of contents, design features and emissions.”
Most countries hesitate to implement policies, due in part to the highly technical nature of such policy interventions and the difficulties in translating science into regulation, explains Dr Vinayak Prasad, who leads WHO’s Tobacco Free Initiative.
“Failure to regulate represents a missed opportunity as tobacco product regulation, in the context of comprehensive control, is a valuable tool that complements other tried and tested tobacco control interventions, such as raising taxes, and ensuring smoke-free environments,” adds Dr Prasad.
“Tobacco product regulation: Building laboratory testing capacity” provides practical, stepwise approaches to implementing tobacco testing. Such guidance is relevant to a wide range of countries in various settings, including those with inadequate resources to establish a testing facility. This laboratory guide is a useful resource for countries, and provides regulators and policymakers with comprehensible information on how to test tobacco products, what products to test, and how to use testing data in a meaningful way to support regulation.
Further, it provides a step-by-step guide to developing a testing laboratory, using an existing internal laboratory, contracting an external laboratory, and making use of the available support mechanisms both within WHO and externally. This calls for country prioritization and commitment of resources to tobacco product regulation, as the guide equips regulators with the necessary tools to strengthen tobacco regulation capacity, especially in relation to Article 9 of the WHO FCTC.
The publication “Case studies for regulatory approaches to tobacco products – Menthol in tobacco products” complements the 2016 advisory note on menthol published by the WHO Study Group on Tobacco Product Regulation, which set out the available evidence on prevalence and health effects of menthol in tobacco products, as well as evidence-based conclusions and recommendations for policy-makers and regulators on menthol in its various forms.
The case studies provide practical guidance and policy options to countries about effective regulatory strategies in tobacco product regulation. This includes lessons learned and challenges encountered in developing and implementing menthol related regulation. To date, regulators have adopted multiple approaches to restricting the use of menthol. These include a ban in some product categories, a total ban on the use of all flavours and a ban on all products with a perceived menthol flavour. This publication also provides useful information on the merits and drawbacks of various regulatory approaches.
Global Commission for Certification of Poliomyelitis Eradication (GCC) meet in Geneva to review criteria for certification
Global Commission for Certification of Poliomyelitis Eradication (GCC) meet in Geneva to review criteria for certification
On 26-27 February 2018, the Global Commission for Certification of Poliomyelitis Eradication (GCC) met in Geneva, Switzerland, to review the criteria that will need to be met to achieve global certification of wild poliovirus (WPV) eradication.
With fewer cases of WPV reported from fewer countries than ever before, the GCC is accelerating its work to prepare for the eventual certification that WPVs have been eradicated from the world.
As part of this process, the GCC faces two important and challenging tasks:
- obtaining and evaluating convincing evidence of interruption of poliovirus transmission; and,
- obtaining and evaluating evidence that polioviruses will be contained to a high level where they are being held.
Discussions focused on reviewing regional progress in the remaining endemic regions of Africa and the Eastern Mediterranean, defining the parameters that will be used for certification, discussing surveillance requirements including in settings requiring additional data such as conflict settings, and evaluating requirements for safe containment of polioviruses in laboratory settings.
Critically, recognizing the increasing importance of circulating vaccine-derived poliovirus (cVDPV) outbreaks as the world moves towards the eradication of WPVs, the GCC agreed that eligibility for WPV certification must not only entail the demonstrated absence of WPV strains, but also the absence of cVDPVs (for at least 18 months for type 2, and for at least six months for types 1 and 3).
The full report from the meeting will be available upon publication (in March) at www.polioeradication.org.
Background
The certification of WPV eradication takes place when the GCC is satisfied with the evidence that WPV transmission has been successfully interrupted, and in the demonstrated absence of cVDPVs for a period of at least 18 months (for type 2) and six months (f or types 1 and 3). This verification ensures that data and evidence are analysed and validated in the most independent and objective manner.
The GCC is independent of WHO and independent of involvement in national polio vaccination implementation or polio surveillance programmes. WHO Regions are eligible for certification following the absence of WPV from any country in that region from any population source in the presence of certification-standard surveillance. Regional certification is conducted by Regional Certification Commissions (RCCs). Global certification will follow the successful certification of all six WHO regions, and will be conducted by the GCC.
As at 2018, four regions have been certified as free of WPVs: Region of the Americas (1994), the Western Pacific Region (2000), the European Region (2002), and the South-East Asia Region (2014).
For more information, please contact:
Oliver Rosenbauer
Communications Officer
Global Polio Eradication Initiative, World Health Organization
Tel: +41 (0)79 500 6536
Email: rosenbauero@who.int
Or
certification page of the polio eradication website.
Polio Eradication ORG
Women’s empowerment is a public health imperative: WHO
By Dr Poonam Khetrapal Singh, WHO Regional Director for South-East Asia
In the WHO South-East Asia Region and beyond, more than half the population – women – face what is often egregious discrimination. Discrimination in education and the opportunity to learn to read and write. Discrimination in access to nutrition and the chance to grow healthy and strong. And discrimination in the workplace, where women can be subjected to unwanted advances or have their work undervalued or unpaid.
Gender-based discrimination in these and countless other forms is a persistent problem across the South-East Asia Region and throughout women’s lives. But as much as gender-based prejudice and inequality violates human rights, stymies social and economic development, and crushes the hopes and dreams of millions of young girls and women, it also has a grave impact on public health and wellbeing.
Examples abound.
The Region-wide practice of early marriage and pregnancy, for instance, is a direct threat to the health of young women and their children, especially in rural areas. Around six million girls aged 15-19 years give birth in our Region every year, while in four of the Region’s countries the adolescent birth rate is more than 50 per 1000 women aged 15-19 years. This provides immense dangers to the health of young women – dangers that can be avoided via rapid social empowerment (including access to contraception) and the implementation of laws against early marriage.
Gender-based inequities likewise impede women’s access to essential health services, causing a range of adverse outcomes. Start with childbirth: Many deliveries still occur in the home, often in the presence of a birth attendant who is unskilled. This occurs partly as a result of women’s inadequate access to health-related knowledge and a lack of decision-making power, and partly due to ongoing service gaps. Though during the Millennium Development Goal era the Region made world-beating progress in reducing maternal and child mortality, further gains are needed to bring the maternal mortality rate to below 70 per 100 000 births, as per the Sustainable Development Goal target.
Still, there is room for optimism: The Region-wide struggle to end gender-based discrimination and advance women’s empowerment – particularly for rural women and girls – has never been stronger. WHO South-East Asia is proud to champion this cause, reflecting as it does our core values and commitment to human rights, as well as our evidence-based conviction that empowered women create healthier, happier communities that produce transformative change, both locally and globally.
Until full equality is achieved, however, WHO will continue to work with our Member countries to promote and support the health of women and girls. That means continuing to train skilled birth attendants able to provide life-saving services when childbirth becomes complicated. It means continuing to advocate for increased access to contraceptives and the provision of adolescent sexual and reproductive health services. And it means continuing to actively campaign against gender-based violence and harmful practices such as female genital mutilation that can cause life-threatening injuries to young girls and adolescents.
This International Women’s Day, let us acknowledge that gender-based discrimination exists and is a daily occurrence in each of the South-East Asia Region’s countries. Let us understand that it needn’t be this way, and that gender equality can be rapidly achieved with sincere, society-wide resolve. And let us take full stock of the fact that women’s empowerment is more than a tool to advance social or economic ends – that it is a public health imperative, and one that demands our most strident pursuit.
WHO SEARO Media Centre
Kidneys & Women’s Health: Include, Value, Empower
World Kidney Day is a global awareness campaign aimed at raising awareness of the importance of our kidneys.
World Kidney Day comes back every year in March 8. All across the globe many hundred events take place. Awareness about preventive behaviors, awareness about risk factors, and awareness about how to live with a kidney disease.
Mission
World Kidney Day aims to raise awareness of the importance of our kidneys to our overall health and to reduce the frequency and impact of kidney disease and its associated health problems worldwide.
Objectives
- Raise awareness about our “amazing kidneys” Highlight that diabetes and high blood pressure are key risk factors for Chronic Kidney Disease (CKD).
- Encourage systematic screening of all patients with diabetes and hypertension for CKD.
- Encourage preventive behaviours.
- Educate all medical professionals about their key role in detecting and reducing the risk of CKD, particularly in high risk populations.
- Stress the important role of local and national health authorities in controlling the CKD epidemic. On World Kidney Day all governments are encouraged to take action and invest in further kidney screening.
- Encourage Transplantation as a best-outcome option for kidney failure, and the act of organ donation as a life-saving initiative.
On this occasion, World Kidney Day and the International Women’s Day 2018 are commemorated on the same day, offering us the opportunity to reflect on the importance of women’ s health and specifically their kidney health. On its 13th anniversary, World Kidney Day promotes affordable and equitable access to health education, healthcare and prevention for kidney diseases for all women and girls in the world.
